Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, marketing and advertising agencies.Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $242M | $-142M | $-139M | $37M | -49.4% | -4.2% | -66.4% |
| 2024 | $252M | $-567M | $-413M | $46M | -93.0% | 0.3% | 104.1% |
| 2023 | $251M | $-241M | $-202M | $38M | -23.5% | 12.9% | 2702.4% |
| 2022 | $223M | $26M | $-7M | $27M | -0.8% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 241.52 |
| Operating Revenue | 241.52 |
| Cost Of Revenue | 58.25 |
| Gross Profit | 183.28 |
| Operating Expense | 203.86 |
| Research And Development | 34.78 |
| Selling General And Administration | 133.26 |
| Total Expenses | 262.10 |
| Operating Income | -20.58 |
| Total Operating Income As Reported | -224.27 |
| EBITDA | -141.86 |
| Normalized EBITDA | 62.34 |
| EBIT | -197.97 |
| Interest Income | 6.95 |
| Interest Expense | 11.29 |
| Net Interest Income | -4.34 |
| Other Non Operating Income Expenses | 19.86 |
| Other Income Expense | -184.34 |
| Interest Income Non Operating | 6.95 |
| Interest Expense Non Operating | 11.29 |
| Net Non Operating Interest Income Expense | -4.34 |
| Pretax Income | -209.26 |
| Tax Provision | -9.96 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -9.70 |
| Net Income Continuous Operations | -199.30 |
| Net Income From Continuing And Discontinued Operation | -138.93 |
| Net Income From Continuing Operation Net Minority Interest | -138.93 |
| Net Income | -138.93 |
| Net Income Common Stockholders | -138.93 |
| Net Income Including Noncontrolling Interests | -199.30 |
| Normalized Income | 55.56 |
| Diluted NI Availto Com Stockholders | -138.93 |
| Basic Average Shares | 106.65 |
| Diluted Average Shares | 106.65 |
| Reconciled Depreciation | 56.11 |
| Reconciled Cost Of Revenue | 37.95 |
| Total Unusual Items | -204.20 |
| Total Unusual Items Excluding Goodwill | -204.20 |
| Minority Interests | 60.36 |
| Special Income Charges | -204.20 |
| Other Special Charges | 0.51 |
| Impairment Of Capital Assets | 196.06 |
| Restructuring And Mergern Acquisition | 7.62 |
| Gain On Sale Of Security | - |
| Depreciation Amortization Depletion Income Statement | 35.82 |
| Depreciation And Amortization In Income Statement | 35.82 |
| General And Administrative Expense | 51.63 |
| Other Gand A | 51.63 |
| Selling And Marketing Expense | 81.64 |
| Otherunder Preferred Stock Dividend | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Definitive Healthcare Corp.this co. | DH | $96M | -0.69 | 0.34 | -49.4% | -0.74 |
| Aldeyra Therapeutics, Inc. | ALDX | $106M | -3.14 | 2.40 | -76.5% | -1.63 |
| Cardiff Oncology, Inc. | CRDF | $106M | -2.31 | 2.33 | -101.0% | -1.86 |
| Neuronetics, Inc. | STIM | $102M | -2.61 | 4.54 | -174.3% | -5.84 |
| OptimizeRx Corporation | OPRX | $101M |
| - |
| - |
| - |
| - |
| - |
| - |
| 19.67 |
| 0.79 |
| 4.0% |
| 6.26 |
| Heron Therapeutics, Inc. | HRTX | $92M | - | 6.39 | -141.0% | - |
| Outset Medical, Inc. | OM | $88M | -1.07 | 0.69 | -64.3% | -2.46 |
| Aardvark Therapeutics, Inc. | AARD | $86M | -1.49 | 0.81 | -54.0% | -0.63 |
| biote Corp. | BTMD | $84M | 3.10 | -1.43 | -46.2% | 3.25 |
| Peer Median | - | -1.49 | 1.57 | -70.4% | -1.63 | |